Pierre Charles,Élodie Perrodeau,Maxime Samson,Bernard Bonnotte,Antoine Néel,Christian Agard,Antoine Huart,Alexandre Karras,François Lifermann,Pascal Godmer,Pascal Cohen,Catherine Hanrotel-Saliou,Nicolas Martin-Silva,Grégory Pugnet,François Maurier,Jean Sibilia,Pierre-Louis Carron,Pierre Gobert,Nadine Meaux-Ruault,Thomas Le Gallou,Stéphane Vinzio,Jean-François Viallard,Eric Hachulla,Christine Vinter,Xavier Puéchal,Benjamin Terrier,Philippe Ravaud,Luc Mouthon,Loïc Guillevin,French Vasculitis Study Group,Marie Matignon,Olivier Aumaitre,Alexis Régent,Boris Bienvenu,Helder Gil,Marc Fabre,Jean-Marc Galempoix,Anthony Bonnin,Nicolas Noël,Emmanuel Chatelus,Claire Larroche,Nicolas Schleinitz,Isabelle Marie,Christian Lavigne,Stéphanie Mestrallet,Estibaliz Lazaro,Laurent Pérard,Richard Damade,Sébastien Delbes,Hassan Kassem,Irène Jarrin,Mathilde de Menthon,Fabienne Closs-Prophette,Alain Fur,Odile de Bouverie,Éric Daugas,Noémie Jourde-Chiche

Abstract:Background: Biannual rituximab infusions over 18 months effectively maintain remission after a "standard" remission induction regimen for patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Objective: To evaluate the efficacy of prolonged rituximab therapy in preventing AAV relapses in patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) who have achieved complete remission after completing an 18-month maintenance regimen. Design: Randomized controlled trial. (ClinicalTrials.gov: NCT02433522). Setting: 39 clinical centers in France. Patients: 68 patients with GPA and 29 with MPA who achieved complete remission after the first phase of maintenance therapy. Intervention: Rituximab or placebo infusion every 6 months for 18 months (4 infusions). Measurements: The primary end point was relapse-free survival at month 28. Relapse was defined as new or reappearing symptoms or worsening disease, with a Birmingham Vasculitis Activity Score greater than 0. Results: From March 2015 to April 2016, 97 patients (mean age, 63.9 years; 35% women) were randomly assigned, 50 to the rituximab and 47 to the placebo group. Relapse-free survival estimates at month 28 were 96% (95% CI, 91% to 100%) and 74% (CI, 63% to 88%) in the rituximab and placebo groups, respectively, an absolute difference of 22% (CI, 9% to 36%) with a hazard ratio of 7.5 (CI, 1.67 to 33.7) (P = 0.008). Major relapse-free survival estimates at month 28 were 100% (CI, 93% to 100%) versus 87% (CI, 78% to 97%) (P = 0.009), respectively. At least 1 serious adverse event developed in 12 patients (24%) in the rituximab group (with 9 infectious serious adverse events occurring among 6 patients [12%]) versus 14 patients (30%) in the placebo group (with 6 infectious serious adverse events developing among 4 patients [9%]). No deaths occurred in either group. Limitation: Potential selection bias based on previous rituximab response and tolerance. Conclusion: Extended therapy with biannual rituximab infusions over 18 months was associated with a lower incidence of AAV relapse compared with standard maintenance therapy. Primary funding source: French Ministry of Health and Hoffmann-La Roche.

Antiviral treatment with fluoxetine for rituximab‐associated chronic echovirus 13 meningoencephalitis and myofasciitis

Fluoxetine Successfully Treats Intracranial Enterovirus E18 Infection in a Patient with CD79a Deficiency Arising from Segmental Uniparental Disomy of Chromosome 19

Severe enterovirus infections in patients with immune-mediated inflammatory diseases receiving anti-CD20 monoclonal antibodies

A Retrospective Evaluation of the Treatment Effects of Rituximab in Patients with Progressive and Symptomatic Fibrosing Mediastinitis

Balancing immunosuppression and infection: recurrent enterovirus encephalitis in SLE

Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis

Impact of rituximab treatment regime on time to relapse in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.

Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: A randomized trial in 108 patients

Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis

Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial

Three cases with chronic obsessive compulsive disorder report gains in wellbeing and function following rituximab treatment

Antiviral and Anti-Inflammatory Activities of Fluoxetine in a SARS-CoV-2 Infection Mouse Model

Long-term effect of rituximab in a case with late-onset Rasmussen´s encephalitis with anti-ganglioside IgGQ1b and anti-GAD antibodies positivity. Case Report

Clinical and In Vitro Evidence Favoring Immunoglobulin Treatment of a Chronic Norovirus Infection in a Patient With Common Variable Immunodeficiency

Intravenous immunoglobulin bridging to rituximab in NMDAR encephalitis patients non-responders to first-line treatments

Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX

Description et analyse des complications infectieuses chez les patients atteints de SEP et traités par rituximab au sein de la cohorte du CHU de Poitiers

Efficacy and safety of rituximab in autoimmune encephalitis: A meta‐analysis

Treatment Options in Refractory Autoimmune Encephalitis

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial